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Abstract
OBJECTIVES: We analyzed the effects of anti-hedgehog signaling on the 18F-FDG uptake of pancreatic cancer xeno-
grafts (PCXs) using a clinically implemented positron emission tomography (PET)–computer tomography (CT) scanner
with high-resolution reconstruction. METHODS: PCXs from two pancreatic cancer cell lines were developed sub-
cutaneously in nude mice and injected intraperitoneally with a low dose of cyclopamine for 1 week. 18F-FDG PET-CT
was performed using a new-generation clinical PET-CT scanner with minor modifications of the scanning protocol to
adapt for small-animal imaging. The data set was reconstructed and quantified using a three-dimensional workstation.
RESULTS: MiaPaCa-2 cells, which respond to cyclopamine, showed decreased 18F-FDG uptake without a change in
tumor size. For hip tumors, the maximum standardized uptake value (SUVmax) was reduced by −24.5 ± 9.2%, the
average SUV (SUVavg) by −33.5 ± 7.0%, and the minimum SUV (SUVmin) by −54.4 ± 11.5% (P < .05). For shoulder
tumors, SUVmax was reduced by −14.7 ± 7.5%, SUVavg by −12.6 ± 6.3, and SUVmin by −30.3 ± 16.7% (P < .05).
Capan-1 cells, which do not respond to cyclopamine, did not show significant SUV changes. CONCLUSIONS: The
new generations of clinically implemented PET-CT scanners with high-resolution reconstruction detect a minimal
response of PCX to low-dose short-term cyclopamine therapy without changes in tumor size and offer potential for pre-
clinical translational imaging.
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Introduction
New-generation clinical positron emission tomography (PET)–CT
scanners are being used increasingly, particularly at dedicated medical
centers. A large field of view (FOV), advanced point-spread function
(PSF) reconstruction algorithms, and an advanced high-definition
detector technology represent hallmarks of these clinical PET-CT sys-
tems. This technology uses millions of accurately measured PSFs for
iterative reconstruction of the image to produce high-definition PET
images with better full width at half-maximum (FWHM), complete uni-
formity, high resolution, and superior contrast throughout the entire
FOV [1]. In turn, less noise and fewer streak artifacts like those in filtered
back-projection reconstructed images are generated [2]. Therefore, a
corrected partial volume effect, increased quantification accuracy, and
improved sensitivity for detecting small lesions up to 2 mm in size are
landmarks of this new technology, rendering PET-CT imaging an opti-
mal diagnostic tool in the diagnosis, therapy planning, and follow-up after
treatment of different cancers [3,4].
Small animals such as tumor-bearing mice are usually imaged using
a dedicated small-animal (DSA) PET scanner. Similar to the new
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generations of the clinical PET-CT scanners, DSA-PET devices use
the advanced reconstruction algorithms that model PSF of individual
detector elements [1,5–7]. This improves spatial resolution of the
small-animal scans. However, DSA-PET scanners are less available,
costly, and use complicated operating protocols. These limitations were
overcome in successful trials using new generations of PET-CT scanners
for imaging of small animals with results comparable to those for DSA-
PET scanners [8–10]. Recently, the effects of novel targeted therapies
such as the tyrosine kinase inhibitors imatinib and sunitinib in gastro-
intestinal stromal tumor xenografts in nudemice could be evaluated using
a clinical PET-CT scanner [11].
Hedgehog signaling contributes to the pathogenesis and progression
of pancreatic cancer. Inhibiting the oncogenic receptor of hedgehog
signaling smoothened (Smo) using hedgehog antagonists, such as the
steroidal veratrum alkaloid cyclopamine, reduces pancreatic cancer cell
growth and metastasis [12–15]. The suppression of hedgehog signal-
ing pathway is associated with decreased accumulation of the hedgehog
transcription factor glioma associated antigen (Gli1) in pancreatic can-
cer cells [12]. Additionally, hedgehog inhibition using cyclopamine
prolongs survival in a genetically engineered mouse model of pancreatic
cancer [15]. Therefore, clinical PET-CT imaging of pancreatic cancer
xenografts (PCXs) after anti-hedgehog therapy might be valuable in
simultaneously providing information about the anatomic, functional,
and metabolic status of these tumors in preclinical settings. This can be
confirmed by analyzing the expression of hexokinase II (HK2), which
is a marker for the cellular glucose metabolism [16]. In this study, we
quantitatively analyzed the known inhibitory effects of cyclopamine
therapy on the 18F-FDG uptake of subcutaneous PCX using a clinically
implemented, latest generation PET-CT scanner as an alternative to
DSA-PET systems. This might extend the availability and reduce the
costs of small-animal imaging and drug testing.
Materials and Methods
Animal Model
MiaPaCa-2 and Capan-1 pancreatic cancer cells, which express high
and low Smo mRNA levels, respectively [13], were grown until 50%
to 70% confluence in RPMI 1640 medium and Dulbecco’s modified
Eagle’s medium, respectively (Life Technologies, Karlsruhe, Germany),
and supplemented with 10% fetal calf serum (FCS; Sigma-Aldrich,
St Louis, MO) and 100 U/ml penicillin/streptomycin (Life Technolo-
gies). Cells were harvested at a density of 1 × 106 cells in 500 μl 1×
phosphate-buffered saline (PBS) and then injected subcutaneously
into the right shoulder and left hip regions of 8-week-old NMRI-nu
(nu/nu) mice (Charles River Laboratories, Maastricht, The Netherlands).
Tumor size was determined daily, starting on the fourth day after
subcutaneous cell inoculation in all groups, until the tumor reached
a diameter of 8 to 9 mm [12]. Cyclopamine (ENZO Life Sciences
GmbH, Loerrach, Germany) was complexed with 2-hydroxypropyl-β-
cyclodextrin (Sigma) and PBS [17]. Then, the cyclopamine suspension
or placebo (2-hydroxypropyl-β-cyclodextrin and PBS) was injected intra-
peritoneally daily for 7 days at a dose of 0.6 mg per mouse. Treatment
with cyclopamine or placebo was initiated simultaneously for all mice.
An experienced technician measured tumor size daily under therapy
for 7 days. A final total number of 12 mice divided into four groups
were used in the study. For each pancreatic cancer cell line, three mice
were treated with cyclopamine and three mice were treated with placebo.
All animals were maintained in a sterile environment in special cages
with filter hoods in a scantainer (Scanbur, Koge, Denmark) on a daily
12-hour light/dark cycle. Cages, bedding, and water were autoclaved
and the chow was sterilized by gamma radiation. All manipulations
were conducted under aseptic conditions using a laminar flow hood.
In accordance with guidelines for animal welfare, all experiments were
approved according to federal and local laws (Baden-Wuerttemberg,
Karlsruhe,Germany) and compliedwith Institutional Regulation License
No. 35-9185.81/G-178/09.
PET-CT Imaging
At the end of the treatment period, tumor-bearing mice ranging in
weight from 34.6 to 39.2 g were fasted for 6 hours before the PET-CT
examination. Mice received general anesthesia using a mixture of keta-
mine (75–100 mg/kg) and xylazine (15–20 mg/kg) [18]. 18F-FDG
[ZAG Zyklotron, Karlsruhe, Germany; 7.4 MBq (200 μCi), in 150 μl
of 0.9% NaCl solution] was injected intravenously into the tail vein
using a G30 needle. Immediately after injecting 18F-FDG, mice were
positioned in prone position on a warm polystyrene or plastic pad to
maintain their body temperature. Imaging studies were performed with
a clinical PET-CT system (Biograph high-definition 40 slice mCT,
Siemens Healthcare Sector, Erlangen, Germany). CT scans were ac-
quired using a tube voltage of 80 kV, tube current of 120 mA, slice
collimation of 0.6 mm, rotation time of 1 second, and kernel B31f for
reconstruction. A high-resolution PET examination was performed
five consecutive times using an acquisition time of 10 min/bed position
to provide a dynamic curve of FDG uptake over 50 minutes (Table 1).
PET images were reconstructed using an iterative mode (attenuation-
weighted, three iterations and 24 subsets, matrix size of 512, zoom
of 10 isotropic, and CT resolution of 0.24 mm with 2-mm uniform
resolution throughout the FOV).
Data Analysis
PET and CT images were loaded to a three-dimensional workstation
for data analysis. With the image analysis software, hybrid images ac-
quired over a period of time can be accurately coregistered, compared,
and quantified simultaneously on a display. The CT images were
coregistered with the PET images to produce fusion images. Data
were evaluated using the ellipsoid isocontour icon (volume-of-interest
[VOI]), which was determined around PCX where maximum diameter
is seen in the fused PET-CT images, to avoid partial volume effects
(Figure 1). The uptake indexwas normalized to the loaded tracer activity,
loading time point, and the body weight of the mouse. Tracer uptake by
the tumors was quantified as standardized uptake value (SUV) using the
following formula: SUV = tissue activity concentration (Bq/ml)/[injected
dose (Bq)/body weight (g)]. Consequently, the 18F-FDG uptake was
calculated as tracer uptake and quantified as an SUV.
Table 1. Parameters for Image Reconstruction after PET Acquisition.
Function Reconstruction
Acquisition time 10 min/bed
Output image type Corrected
Iteration/subset 3/24
Size of image 200
Matrix 512
Zoom 10
Gaussian filter 1 mm and 3 mm
Scatter correction Active
Match CT slice location Active
Volume scaling Active
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Tissue Sampling and Ex Vivo 18F-FDG Uptake
Immediately after PET-CT imaging, all mice were sacrificed by
cervical dislocation. Major organs such as liver and spleen as well
as tumors were excised, and the 18F-FDG uptake was assessed ex vivo
by using an r-well gamma counter (PTW Curiementor, Freiburg,
Germany). Then, the excised PCX were preserved in 4% parafor-
maldehyde for 24 hours and transferred into 70% ethanol until tissue
processing and embedding in paraffin took place.
Immunohistochemistry
Paraffin-embedded tissue sections of 2- to 3-μm thickness were
deparaffinized in xylene and rehydrated in progressively decreasing
concentrations of ethanol. Thereafter, the slides were placed in wash-
ing buffer (10 mM Tris-HCl, 0.85% NaCl, 0.1% BSA, pH 7.4) and
subjected to immunostaining. Antigen retrieval was performed by boil-
ing tissue sections in 10 mM citrate buffer for 10 minutes in a micro-
wave oven. Tissue sections were incubated with the following specific
primary antibodies: rabbit anti-human Gli1 (Santa Cruz Biotechnology,
Santa Cruz, CA) and rabbit anti-human HK2 (Cell Signaling Technol-
ogy, Inc, Danvers, MA). The corresponding normal immunoglobulins
(IgGs) were used as negative controls. The slides were then rinsed with
washing buffer and incubated with the corresponding horseradish
peroxidase (HRPO)-conjugated secondary antibodies for 1 hour at room
temperature. Tissue sections were then washed in washing buffer, and
3-3′-diaminobenzidin (DAB) chromogen/substrate mixture (Dako,
Hamburg, Germany) was applied to each section. Slides were analyzed
by two experienced investigators using a LeicaDMRBmicroscope (Leica,
Bensheim, Germany).
Statistical Analysis
For statistical analysis, the two-tailed nonparametric Mann-Whitney
test was used to compare SUVs. Significance of results was defined
as P < .05.
Results
In Vivo Tumorigenicity
On day 7 of treatment before the PET-CT examination, the mean
diameter of the hip PCX from the control MiaPaCa-2 cells was 12.3 ±
1.2 mm and from the cyclopamine-treated cells 11.7 ± 0.9 mm. The
mean diameter of the shoulder PCX from the control MiaPaCa-2 cells
was 10.7 ± 0.5 mm and from the cyclopamine-treated cells 12.0 ±
1.4 mm. In contrast, the mean diameter of the hip PCX from the
control Capan-1 cells was 10.6 ± 0.5 mm and from the cyclopamine-
treated cells 10.3 ± 0.9 mm. The mean diameter of the shoulder
PCX from the control Capan-1 cells was 9.0 ± 0.8 mm and from the
cyclopamine-treated cells 8.3 ± 0.9 mm. No significant difference was
Figure 1. Registration of VOIs in PCX. PCX were grown in the hip region (upper row) and shoulder region (lower row) of nude mice and
treated with placebo (left images) or cyclopamine (right images). VOIs were determined in the PET/CT images for PCX as described in
Materials and Methods. The absolute SUVmax, SUVavg, and SUVmin are displayed.
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observed between the cyclopamine-treated and placebo groups, with
P > .05 (Figure 2).
Change in SUV of PCX In Vivo
The main values obtained were minimum SUV (SUVmin), maximum
SUV (SUVmax), and average SUV (SUVavg) expressed as a percent of
control placebos (100%). In MiaPaCa-2 cells, which express Smo re-
ceptor and respond to cyclopamine, 18F-FDG uptake was decreased.
Forty-five minutes after injecting 18F-FDG, SUVmax for the hip tumors
had decreased by −24.5 ± 9.2%, SUVavg by −33.5 ± 7.0%, and SUVmin
by −54.4 ± 11.5% (P < .05; Figure 3, A–C). A significant reduction (P <
.05) in SUVmax by −14.7 ± 7.5%, SUVavg by −12.6 ± 6.3, and SUVmin by
−30.3 ± 16.7% could also be observed in the shoulder tumors (Figure 3,
D–F ). In Capan-1 cells, which do not express the Smo receptor, no
significant change in 18F-FDG uptake could be observed in response
to cyclopamine therapy (Figure 3).
Absolute SUVmax of PCX
The maximum change in SUVmax of PCX was observed in the PET
images obtained after 45minutes. Therefore, we compared the absolute
SUVmax of PCX from the two pancreatic cancer cell lines in vivo and
ex vivo. In vivo, the SUV for placebo-treated PCX from MiaPaCa-2
cells in the hip regions ranged from 5.6 to 8.4, but for cyclopamine-
treated PCX, SUV ranged from 5.1 to 6.4. Ex vivo, placebo-treated
PCX from MiaPaCa-2 cells in the hip regions showed an SUV range
of 7.8 to 8.8, but cyclopamine-treated PCX showed an SUV range of
5.6 to 8.2. In vivo, the SUV for placebo-treated PCX from MiaPaCa-2
cells in the shoulder regions ranged from9.4 to 19.1, but for cyclopamine-
treated PCX, SUV ranged from 6.1 to 11.4. Ex vivo, placebo-treated
PCX from MiaPaCa-2 cells in the shoulder regions showed an SUV
range of 6.6 to 19.8, but cyclopamine-treated PCX showed an SUV
range of 2.2 to 18.4. This indicates a decrease in SUVmax of PCX from
MiaPaCa-2 cells after cyclopamine therapy both in vivo and, as con-
firmed by a similar reduction in the calculated SUV of these PCXs,
ex vivo (Figure 4A).
In contrast, for placebo-treated PCX from Capan-1 cells in the hip re-
gions, SUV ranged from 7.8 to 12.3, but for cyclopamine-treated PCX,
SUV ranged from 9.8 to 12.4 in vivo. Ex vivo, placebo-treated PCX from
Capan-1 cells in the hip regions showed an SUV range of 8.6 to 14.8,
but cyclopamine-treated PCX showed an SUV range of 10.3 to 12.3.
In vivo, for placebo-treated PCX from Capan-1 cells in the shoulder
regions, SUV ranged from 6.7 to 21.4, but for cyclopamine-treated
PCX, SUV ranged from 16.1 to 18.8. Ex vivo, placebo-treated PCX
from Capan-1 cells in the shoulder regions showed an SUV range
of 6.7 to 45.6, but cyclopamine-treated PCX showed an SUV range
of 12.1 to 60.8. This indicates no change in SUVmax of PCX from
Capan-1 cells after cyclopamine therapy either in vivo or, as confirmed
by the calculated SUV of these PCXs, ex vivo (Figure 4B).
PCX/Liver Ratio
To confirm successful fasting of mice and to validate the data obtained
by measuring the absolute SUVmax in PCX, we calculated the
18F-FDG
uptake both in vivo (SUV) and ex vivo (MBq) for both PCX and liver as
tumor-to-liver ratio (T/L ratio). In vivo, T/L ratio of placebo-treated PCX
from MiaPaCa-2 cells in the hip regions ranged from 0.77 to 0.94, but
the ratio of cyclopamine-treated PCX ranged from 0.39 to 0.6
(Figure 5A). Ex vivo, placebo-treated PCX from MiaPaCa-2 cells in the
hip regions showed an SUV range of 0.16 to 0.36, but cyclopamine-
treated PCX showed an SUV range of 0.03 to 0.19 (Figure 5B). In vivo,
T/L ratio of placebo-treated PCX from MiaPaCa-2 cells in the shoulder
Figure 2. In vivo tumor growth of PCX during therapy. PCX fromMiaPaCa-2 cells (A and B) and Capan-1 cells (C and D) were treated with cyclo-
pamineor placebo. Thediameter of thePCXwasmeasuredduring treatment over 7days for tumorsgrown in thehip region (AandC) and shoulder
region (B and D) of nude mice as described in Materials and Methods. The data are expressed as the mean diameter ± SEM. P> .05.
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regions ranged from 1.4 to 2.5, but the ratio of cyclopamine-treated PCX
ranged from 0.9 to 1.6 (Figure 5A). Ex vivo, placebo-treated PCX from
MiaPaCa-2 cells in the shoulder regions showed an SUV range of 0.12
to 0.36, but cyclopamine-treated PCX showed an SUV range of 0.07 to
0.2. This indicates that the range of the T/L ratio in cyclopamine-treated
PCX of MiaPaCa-2 cells was lower than in the placebo group.
In vivo, T/L ratio of placebo-treated PCX from Capan-1 cells in the
hip regions ranged from 0.9 to 1.4, but the ratio of cyclopamine-treated
Figure 4. 18F-FDG uptake (SUV) in tumors in vivo and ex vivo. SUVs of PCX were measured in vivo in the coregistered PET-CT images.
Additionally, the radioactivity uptake of PCX was determined ex vivo and recalculated as SUV as described in Materials and Methods.
In vivo and ex vivo results were blotted as individual values for the cyclopamine-treated and its corresponding placebo-treated PCX of both
MiaPaCa-2 (A) and Capan-1 (B). The results are plotted as individual values of cyclopamine-treated and corresponding placebo-treated PCX.
The experiments were repeated three times.
Figure 3. 18F-FDG uptake of PCX with PET-CT. PCX from MiaPaCa-2 cells (continuous line) and Capan-1 cells (interrupted line) were grown
in the hip region (A–C) and shoulder region (D–F) of nude mice and treated with cyclopamine and scanned with the clinically implemented
PET-CT scanner, and the images were analyzed as described in Materials and Methods. After cyclopamine therapy, SUVs were calculated
as a percentage of control placebos (100%). The data are expressed as the mean SUVs in three different experiments ± SEM. P < .05.
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PCX ranged from 0.9 to 1.2 (Figure 5A). Ex vivo, placebo-treated
PCX from Capan-1 cells in the hip regions showed an SUV range
of 0.03 to 0.27, but cyclopamine-treated PCX showed an SUV range
of 0.23 to 0.27 (Figure 5B). In vivo, T/L ratio of placebo-treated
PCX from Capan-1 cells in the shoulder regions ranged from 0.9 to
2.3, but the ratio of cyclopamine-treated PCX ranged from 1.5 to
2.2 (Figure 5A). Ex vivo, placebo-treated PCX from Capan-1 cells
in the shoulder regions showed an SUV range of 0.03 to 0.3, but
cyclopamine-treated PCX showed an SUV range of 0.18 to 0.5
(Figure 5B). This indicates no change in the range of the T/L ratio
in cyclopamine-treated PCX of Capan-1 cells compared to the
placebo group.
Figure 5. In vivo and ex vivo measurements of the 18F-FDG uptake T/L ratio. 18F-FDG uptake was measured in vivo (A) as SUV and
ex vivo (B) as MBq for both PCX and livers of mice. The T/L ratio was calculated and blotted as individual values for the cyclopamine-treated
and its corresponding placebo-treated PCX in bothMiaPaCa-2 and Capan-1 PCX. The results were plotted as individual values of cyclopamine-
treated and corresponding placebo-treated PCX. The experiments were repeated three times.
Figure 6. Immunohistochemistry staining of placebo-treated and cyclopamine-treated PCX from MiaPaCa-2 cells. PCX were treated with
placebo (A and C) or cyclopamine (B and D), then excised after PET-CT scanning, and immunohistochemistry was performed using specific
antibodies for HK2 (A and B) and Gli1 (C and D) as described in Materials and Methods. Note the moderately increased staining intensity in
the placebo-treated PCX compared to cyclopamine-treated PCX. Lower insets are magnified images to demonstrate the cellular localization
of both HK2 and Gli1 (arrows), aswell as the difference in staining. The specificity of immunostainingwas confirmed using a negative control
rabbit IgG in a consecutive tissue section (B; upper inset). A magnification scale of 100 μm was used to capture images.
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Immunohistochemistry
To confirm the results obtained by PET-CT at the cellular level, we
performed immunohistochemical studies for PCX using a marker for
glucose metabolism HK2 and Gli1 transcription factor of the hedgehog
signaling pathway. The immunostaining for PCX from MiaPaCa-2
cells was qualitatively slightly less intense for both HK2 and Gli1 in re-
sponse to cyclopamine than in placebo (Figure 6, A–D). In contrast,
PCX from Capan-1 cells, with or without cyclopamine therapy, did
not show any changes in the immunostaining intensity for either
HK2 or Gli1 (Figure 7, A–D). The specificity of immunostaining
was confirmed by using the corresponding control IgG (Figure 7, A
and inset).
Discussion
DSA-PET is used to study animal models in preclinical research. DSA-
PET is a sequential noninvasive imaging technique, providing high-
resolution CT images and precise localization of PET findings that
can more accurately estimate radioactivity concentration through par-
tial volume corrections. Many recent studies have demonstrated the
potential use of clinical PET-CT scanners in small-animal imaging
[10,19]. In contrast to DSA-PET imaging systems, less molecular/
metabolic information is obtained when imaging small tumors in mice
using conventional clinical PET scanners. This is because of the low
spatial resolution and low sensitivity of the back-projection techniques
during image reconstruction [10]. This problem could be overcome to
a large extent by using advanced reconstruction algorithms that modu-
late the PSF of the PET-CT detectors, increasing the spatial resolution
for imaging small lesions in mice [7,8]. Additionally, the new genera-
tions of PET-CT imaging systems have been developed to overcome
the variability in quantitative results because of software and hardware
challenges in conventional scanners. The advanced clinical PET-CT
system offers accurate and reproducible quantification in PET-CT
imaging by optimizing the volumetric image resolution, daily system
calibration, accuracy of attenuation correction using accurate coregistra-
tion algorithms, and user-independent reproducible SUV calculation
methods. Nowadays, these technical developments are considered to
be a cornerstone in radiotherapy planning and follow-up of subtle
tumor changes after therapy [20–23].
In the present study, clinical PET-CT served as the basis for transla-
tional small-animal imaging, using dedicated clinical imaging protocols
established for humans with minor modifications of the scanning pro-
tocol. Increasing the zoom to 10 and PET acquisition time to 10 min/
bed position has helped greatly to overcome the discrepancy between
the body mass of mice and humans, which negatively affects the
isotropic and temporal spatial resolution of PET-CT in conventional
scanners with a back-projection function [10].
By repeating the 10 min/bed position scan five times instead of the
standard 3 min/bed position applied for humans, we could monitor
18F-FDG uptake dynamically over 50 minutes. We observed a differ-
ence in the dynamic uptake between PCX from MiaPaCa-2 cells and
Capan-1 cells, which reflects the difference in the metabolic activity in
the two cell lines and—in turn—might be attributed to the hetero-
geneous genetic and epigenetic profile of pancreatic cancer cells and
their differing responses to therapy. The investigation of 18F-FDG
uptake in PCX from many different pancreatic cancer cell lines in clini-
cal settings might be investigated in future studies to determine the
individual metabolic profile for each cell line in vivo.
Figure 7. Immunohistochemistry staining of placebo-treated and cyclopamine-treated PCX from Capan-1 cells. PCX were treated with
placebo (A and C) or cyclopamine (B and D), then excised after PET-CT scanning, and immunohistochemistry was performed using specific
antibodies for HK2 (A and B) and Gli1 (C and D) as described in Materials and Methods. Note the unchanged brown staining intensity in the
placebo-treated PCX compared to cyclopamine-treated PCX. Lower insets are magnified images to demonstrate theweak cellular localization
of HK2 and Gli1 as well as the staining intensity. A magnification scale of 100 μm was used to capture images.
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To avoid bias in the in vivo measurement of the SUVs, we recal-
culated the SUVs of tumors after measuring their radioactivity uptake
ex vivo using a scintillation counter in both the cyclopamine-treated
group and the placebo group in both cell lines. The difference in
18F-FDG uptake of cyclopamine-treated and placebo MiaPaCa-2
PCX in vivo matched the recalculated SUVs ex vivo as well as the
radioactivity uptake ex vivo. Additionally, to further confirm the re-
duced 18F-FDG uptake after cyclopamine therapy and to confirm a
successful fasting of mice, the T/L ratio was calculated in vivo and
ex vivo. The data obtained from this evaluation corresponded to the
absolute SUVs obtained by VOIs determined in the coregistered
PET-CT images. Thus, bias of successful fasting was excluded and
the effects of cyclopamine therapy were confirmed by using the liver
as an internal control in vivo and ex vivo. Taken together, these data
indicate that the clinical PET-CT system is a useful tool for evaluating
tumors in small-animal models.
The gold standard for detecting and staging pancreatic cancer is
multidetector CT combined with endoscopic ultrasound examination
[24]. However, the role of 18F-FDG PET-CT for diagnosis, staging,
and follow-up of patients with pancreatic cancer has been thoroughly
discussed [25]. Despite these advances, the prognosis for pancreatic
cancer has not significantly changed in decades, with a 5-year survival
of less than 5% [26]. Therefore, new therapeutic agents that target
specific signaling pathways involved in pancreatic carcinogenesis need
to be implemented for the treatment of this dismal disease. One of the
promising new candidates is antagonizing hedgehog signaling [27].
The inhibition of pancreatic cancer cell growth by antagonizing the
hedgehog signaling pathway using cyclopamine has been demonstrated
in vitro and in vivo [12–15]. Most of these studies used high-dose
cyclopamine and a long treatment period. The design of the current
study aimed at determining the ability of the clinical PET-CT system
to detect minimal changes in the metabolic activity of very small PCX
treated with cyclopamine at a low dose and over a short period of
time. The clinical PET-CT system could detect a subtle decrease in
the 18F-FDG uptake of PCX after treatment with cyclopamine. This
has been shown at the level of SUVmin, SUVmax, and—in turn—
SUVavg of
18F-FDG by PCX, which reflects the potentially high sensi-
tivity of the clinical PET-CT system in detecting the minimal response
to anti-hedgehog therapy of PCX, even in the absence of detectable
changes in tumor size. Data reporting the high accuracy of the new
generations of the clinically implemented PET-CT scanners in moni-
toring the response of gastrointestinal stromal tumor xenografts after
targeted anti-tyrosine kinase therapy support these results [11].
The hedgehog signaling cascade is activated through ligand/receptor
binding, causing overexpression and cytoplasmic/nuclear accumulation
of Gli1 transcription factor in a feedback mechanism [28,29]. Hedge-
hog signaling molecules, including Gli1, are overexpressed in pancreatic
cancer and could be downregulated after therapy with cyclopamine
[12–15]. The expression of hedgehog signaling molecules depends
highly on the type of cancer cells. For example, the oncogenic receptor
Smo is overexpressed in MiaPaCa-2 pancreatic cancer cells, in contrast
to Capan-1 pancreatic cancer cells, which do not express this receptor
[13]. As a result, MiaPaCa-2 cells respond to cyclopamine therapy by
inhibiting their growth in vitro, which is in contrast to Capan-1 cells
[13]. Activated hedgehog signaling pathway is associated with the accu-
mulation of Gli1, which could be reversed by cyclopamine in pancre-
atic cancer cells [12]. We have shown in the current study that both the
SUVs and Gli1 accumulation were slightly decreased in MiaPaCa-2
cells of PCX in response to low-dose and short-term therapy with
cyclopamine. In contrast, these changes were not seen in Capan-1 cells.
Additionally, HK2 is a known marker for glucose metabolism [16].
The slight reduction in metabolic activity and glucose consumption
of PCX from MiaPaCa-2 cells was also confirmed by the slight reduc-
tion in intracellular accumulation of HK2 after cyclopamine therapy
compared to PCX from Capan-1 cells. This again reflects the high
sensitivity of the clinically implemented PET-CT system in detecting
subtle changes in 18F-FDG uptake by PCX after low-dose and short-
term therapy, which is in agreement with the immunohistologic find-
ings. Importantly, these changes occurred in the absence of size changes,
which demonstrates the efficacy of the clinical PET-CT in the preclinical
assessment of new targeted molecular anticancer drugs.
The main limitation of this study is the lack of baseline clinical
PET-CT imaging and repeated PET-CT monitoring of PCX before
and during treatment. Regulations for animal housing facilities do not
allow mice to be transported for scanning with the clinical PET-CT
scanner more than once for hygienic and ethical reasons. Therefore,
baseline clinical PET-CT imaging was not possible owing to the dif-
ferent locations of the animal facility and clinical PET-CT system. To
overcome this bias, we considered the SUVs of placebo-treated PCX as a
100% uptake of tracer. Then, the SUVs obtained for the cyclopamine-
treated PCX were calculated as a percentage reduction of tracer uptake
in placebo PCX. Additionally, we compared PCX of the same size from
a homogeneous population of the same pancreatic cancer cell line and
without any apparent change in the size of PCX owing to a short-term
low-dose therapy. Therefore, the metabolic profile is expected to be
the same as if baseline imaging had been performed. However, this
logistic problem should be resolved in future studies.
In conclusion, we demonstrated that a clinical PET-CT system
equipped with PSF could monitor the effects of preclinical therapeutic
agents in PCX developed into nude mice. The new generations of
the clinically implemented PET-CT scanners with high-resolution re-
construction might be useful tools for translational imaging, especially
for evaluating new anti-tumor therapies for pancreatic cancer. How-
ever, small-animal PET-CT systems that have a better spatial resolution
should be used if available.
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